Phase I/II Trial of PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)
Phase of Trial: Phase I/II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs Pexidartinib (Primary)
- Indications Leukaemia; Neurofibromatoses; Plexiform neurofibroma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 02 Jun 2017 Results (n=14) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 23 May 2017 According to a Daiichi Sankyo Company media release, data from the study will be presented at the 2017 American Society for Clinical Oncology (ASCO) Annual Meeting.
- 01 Feb 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2018.